Pilot Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Latest Information Update: 23 Aug 2024
Price :
$35 *
At a glance
- Drugs Bendamustine (Primary) ; Devimistat (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Adverse reactions
- 18 Jul 2024 Status changed from recruiting to discontinued.
- 13 May 2024 Planned primary completion date changed from 1 May 2024 to 1 Nov 2024.
- 12 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.